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ABSTRACT
Prostate cancer is the third most common cause of male cancer death in 
developed countries, and one of the most comprehensively characterized human 
cancers. Roughly 60% of prostate cancers harbor gene fusions that juxtapose ETS-
family transcription factors with androgen regulated promoters. A second subtype, 
characterized by SPINK1 overexpression, accounts for 15% of prostate cancers. 
Here we report the discovery of a new prostate cancer subtype characterized by 
rearrangements juxtaposing the SMAD inhibitor SKIL with androgen regulated 
promoters, leading to increased SKIL expression. SKIL fusions were found in 6 of 
540 (1.1%) prostate cancers and 1 of 27 (3.7%) cell lines and xenografts. 6 of 
7 SKIL-positive cancers were negative for ETS overexpression, suggesting mutual 
exclusivity with ETS fusions. SKIL knockdown led to growth arrest in PC-3 and 
LNCaP cell line models of prostate cancer, and its overexpression led to increased 
invasiveness in RWPE-1 cells. The role of SKIL as a prostate cancer oncogene lends 
support to recent studies on the role of TGF-β signaling as a rate-limiting step in 
prostate cancer progression. Our findings highlight SKIL as an oncogene and potential 
therapeutic target in 1-2% of prostate cancers, amounting to an estimated 10,000 
cancer diagnoses per year worldwide.
INTRODUCTION
Prostate cancer is diagnosed in over 900,000 
men worldwide every year, making it the second most 
common cancer among men [1]. The standard-of-care 
for localized prostate cancer is radical prostatectomy or 
radiation therapy, whereas advanced tumors are treated 
with systemic therapies that inhibit androgen signaling 
[2]. More specific drug targets and driver mutations have 
been sought through extensive genomic characterization 
efforts [3,4]. We now know that genomic rearrangement 
plays a major role in the onset of prostate cancer, with 
60% of tumors harboring chromosomal rearrangements 
that juxtapose androgen regulated promoters with the ETS 
family transcription factors ERG, ETV1, ETV4 or FLI1 
[5,6]. However, the products of these fusion genes have 
proven difficult to target with small molecule inhibitors. 
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More recently, overexpression of the trypsin inhibitor 
SPINK1 was found to define a second prostate cancer 
subtype mutually exclusive with ETS overexpression [7]. 
Monoclonal SPINK1 antibodies have shown efficacy in 
preclinical models [8], suggesting that SPINK1 inhibition 
may prove a beneficial treatment strategy in the 15% of 
prostate cancers positive for SPINK1 overexpression. 
Recent studies have identified other alterations mutually 
exclusive with ETS fusions, including mutations in the 
SPOP gene [4], and deletions of the chromatin remodeling 
gene CHD1 [9]. Despite these discoveries, a significant 
fraction of prostate cancers do not harbor any of the above 
alterations.
In addition to ETS fusions and associated events, 
genomic characterization studies have identified non-
synonymous mutations in TP53, MED12, and PTEN 
[3,4,10], and gross deletions of the tumor suppressor 
genes PTEN, RB1 and TP53 [3,4,10]. More recently, a 
number of studies have highlighted the role of attenuated 
TGF-β signaling in prostate cancer progression [11–13]. 
SMAD4, a critical component of the TGF-β signaling 
cascade, is inactivated in a subset of advanced prostate 
cancers through promoter hypermethylation [14] or 
somatic mutation [10], and its expression is reduced in 
metastatic prostate cancer [11]. Mouse studies have shown 
that TGF-β signaling inhibits progression of PTEN-null 
tumors, and that SMAD4 deletion can overcome this 
inhibition [11]. In pancreatic adenocarcinoma, biallelic 
inactivation of SMAD4 is observed in 50% of tumors [15].
In this study, we performed transcriptome and low-
coverage whole genome sequencing on 28 untreated and 
13 castration resistant prostate cancers, and identified a 
new prostate cancer subtype characterized by activating 
rearrangements of the SMAD inhibitor SKIL.
RESULTS
Sample acquisition and sequencing
Fresh-frozen tissue from 12 benign prostatic 
hyperplasias (BPH), 28 untreated prostate cancers (PC), 
and 13 castration resistant prostate cancers (CRPC) 
was acquired from the Tampere University Hospital 
(Tampere, Finland). All samples contained a minimum 
of 70% cancerous or hyperplastic epithelial cells. PC 
samples were obtained by radical prostatectomy and 
locally recurrent CRPCs by transurethral resection of the 
prostate (Supplementary Table 1). Mean age at diagnosis 
was 60.8 years (range: 47.4-71.8) and mean PSA at 
diagnosis was 10.8 ng/ml (range: 3.5-48.1). Libraries were 
prepared for paired-end analysis on the Illumina HiSeq 
2000. On average, we obtained 150 million paired end 
reads per sample from the low coverage whole genome 
sequencing, and 110 million paired end reads from the 
whole transcriptome sequencing (Supplementary Table 2).
Discovery of recurrent SKIL-activating 
rearrangements
Fusion events involving an ETS family transcription 
factor or SPINK1 overexpression were identified in 32 of 
41 tumors based on transcriptome sequencing (Figure 
1a, Supplementary Table 3). No SPOP mutations were 
identified in our cohort. We identified a novel TMPRSS2-
SKIL fusion gene in one CRPC sample (Figure 1A-
B, Supplementary Figure 1) and validated it using 
Sanger sequencing (Figure 1B) and fluorescence in situ 
hybridization (Figure 1C). The fusion merged the first 
three exons of TMPRSS2 with full length SKIL and led 
to SKIL overexpression due to the androgen regulated 
TMPRSS2 promoter (Figure 1D). SKIL encodes a SKI-
like protein that inhibits TGF-β signaling by binding to 
and disrupting the heteromeric SMAD complex [16]. To 
search for more positive cases, we screened 76 additional 
tumors (Supplementary Table 1) and 22 LuCaP xenografts 
with qRT-PCR, and identified SKIL overexpression in 
one xenograft and one clinical sample. Transcriptome 
sequencing of these samples revealed a SLC45A3-SKIL 
fusion in LuCaP-77 and a MIPEP-SKIL fusion in the 
clinical sample, confirming SKIL as a recurrent 3’ fusion 
partner in prostate cancer (Figure 1E-F). Analysis of 
transcriptome sequencing data from the Cancer Genome 
Atlas (TCGA) prostate adenocarcinoma project revealed 
additional SKIL-activating rearrangements in 4 of 423 
samples, with concomitant SKIL overexpression (Figure 
2A-B). In the Taylor et al. dataset, two ETS-negative 
samples (PCA0015 and PCA0056) exhibited outlier 
overexpression of SKIL, but were excluded from further 
analysis due to lack of sequencing data [3]. Interestingly, 
all 5 SKIL-positive clinical samples with clinical 
information (two TCGA samples lacked clinical data) 
contained a Gleason grade 5 component or represented 
metastatic prostate cancer, suggesting that SKIL-activating 
alterations may associate with high-grade prostate cancer.
None of the seven SKIL rearrangements disrupted 
the protein coding sequence of SKIL, suggesting that full-
length SKIL protein is necessary for oncogenic function. 6 
of 7 SKIL rearrangements involved an androgen regulated 
promoter, indicating selection towards juxtapositions with 
highly active promoters. 6 of 7 fusion positive samples 
were negative for ETS overexpression, suggesting mutual 
exclusivity between SKIL and ETS rearrangements (p 
= 0.047, Fisher’s exact test). Sample TCGA-YL-A8SJ 
overexpressed both SKIL and ETV1 (Figure 2A), although 
we found no reads supporting an ETV1 rearrangement in 
either the transcriptome or exome sequencing data for this 
sample.
In sample TCGA-HC-7211, the rearrangement 
between ACPP and SKIL had an unexpected structure, 
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Figure 1: Recurrent SKIL-activating rearrangements in prostate cancer. (A) Matrix showing mutually exclusive 
overexpression of ERG, ETV1, ETV4, SPINK1, and SKIL in a transcriptome sequencing cohort of 41 prostate cancers. Red rectangles 
indicate overexpression, and black inner rectangles indicate fusion events. (B) Structure of the TMPRSS2-SKIL fusion gene identified in 
sample CRPC_348. Black lines indicate exon-exon junctions with transcriptome sequencing evidence. Fusion transcript was validated 
with Sanger sequencing from cDNA. (C) Fluorescence in situ hybridization validates the fusion at genomic level. One example of a fusion 
positive cell is shown. (D) SKIL expression in the transcriptome sequencing cohort of 41 prostate cancers and 12 BPHs. SKIL is strongly 
overexpressed in the TMPRSS2-SKIL positive sample. (E) SKIL expression was measured using qRT-PCR in a validation cohort of 76 
prostatectomy samples. Sample PC_11423 exhibited SKIL overexpression and was found to contain a MIPEP-SKIL rearrangement by 
transcriptome sequencing. (F) SKIL expression was measured using qRT-PCR in LuCaP xenografts and cell line models of prostate cancer. 
Xenograft LuCaP-77 was found to contain an SLC45A3-SKIL rearrangement by transcriptome sequencing.
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with the first exon and promoter of ACPP placed 
downstream of SKIL in antisense orientation (Figure 2B). 
Despite the non-canonical structure, the rearrangement 
led to strong overexpression of full-length SKIL (Figure 
2A), possibly due to chromatin remodeling induced by 
the androgen regulated ACPP promoter. The antisense 
promoter provoked expression of a spliced antisense 
transcript composed of cryptic exons located in SKIL 
introns (Supplementary Figure 2). Expression of the 
antisense transcript did not appear to interfere with SKIL 
splicing, as sense transcripts were normally spliced.
Level of nuclear SKIL protein is elevated in a 
fusion positive sample
To determine whether fusion positive clinical 
samples also overexpressed SKIL at the protein 
level, we used a monoclonal antibody to perform 
immunohistochemistry on the fusion positive TURP 
sample CRPC_348 and 8 negative controls. The TURP 
sample exhibited strong nuclear and modest cytoplasmic 
staining for SKIL, while negative controls showed no 
staining or only weak cytoplasmic staining for SKIL 
(Figure 3A). We also showed the overexpression of 
SKIL at the RNA level in CRPC_348 using RNA in situ 
hybridization (Figure 3B).
Figure 2: SKIL-activating rearrangements in the TCGA prostate adenocarcinoma sequencing cohort. (A) Barplot showing 
expression of ERG, ETV1, ETV4, SPINK1 and SKIL in TCGA samples. Four samples exhibited significant SKIL overexpression and were 
found to harbor SKIL-activating rearrangements. (B) Structures of the ACPP-SKIL, SLC45A3-SKIL, MIPOL1-SKIL and HMGN2P46-SKIL 
rearrangements. Black lines indicate exon-exon junctions with transcriptome sequencing evidence.
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SKIL regulates proliferation and invasiveness of 
prostate cancer cells
To better understand the biological role of SKIL in 
prostate cancer cells, we knocked SKIL down in PC-3 
cells using two different siRNA (Figure 4A), and observed 
reduced cell growth (Figure 4B), invasiveness (Figure 4c), 
and colony formation (Figure 4D) relative to scrambled 
siRNA. The effect on cell growth was replicated in LNCaP 
cells (Figure 4E-F). To show that SKIL expression is truly 
androgen dependent in cells where SKIL is fused with 
androgen regulated promoters, we extracted LuCaP-77 
xenograft tissue (with an SLC45A3-SKIL fusion) from 
castrate and non-castrate mice 1, 3 and 7 days post-
castration. We then used qRT-PCR to quantify SKIL and 
KLK3 (PSA) expression at each timepoint. Expression 
values were normalized against TATA-box binding protein 
(TBP) and compared against non-castrate control mice. 
We observed a strong reduction in the expression of both 
KLK3 and SKIL on day 7, indicating androgen regulated 
expression (Figure 4G).
Next, we created a SKIL overexpression model by 
transfecting immortalized prostate epithelial cells (RWPE-
1) with a pCI-Neo vector expressing hemagglutinin (HA) 
tagged SKIL [17]. Control RWPE-1 cells were transfected 
with an empty pCI-Neo vector (EV). In comparison to 
control cells, SKIL-transfected RWPE-1 cells exhibited 
higher expression of SKIL at both RNA and protein levels 
(Figure 5A-B), and greater invasive potential in a matrigel 
invasion assay (n = 3, p = 0.044, unpaired two-tailed t-test) 
(Figure 5C). SKIL overexpression had no effect on the 
growth of RWPE-1 cells (data not shown).
Other genomic alterations in the sequencing 
cohort
A previous study has shown that combined 
deletion of SMAD4 and PTEN in mouse prostates leads 
to aggressive prostate cancer with 100% penetrance [11]. 
Therefore, we set out to check whether SKIL-rearranged 
cancers harbored concomitant PTEN deletions. PTEN 
expression was not aberrantly low in any of the 7 SKIL-
positive cases, and only 1 of 4 SKIL-positive cancers in 
the TCGA cohort showed evidence of PTEN deletion, 
suggesting that SKIL rearrangements do not require 
combined PTEN loss. Genes associated with ERG 
overexpression, such as COL2A1, ALOX15, CRISP3, 
B3GNT6 and TDRD1, were not overexpressed in SKIL-
rearranged tumors.
Figure 3: Immunohistochemistry and RNA in situ hybridization of SKIL in a SKIL-rearranged tumor. (A) Anti-SKIL 
staining of paraffin-embedded sections from the SKIL-rearranged TURP sample CRPC_348 and two representative prostatectomies 
negative for SKIL rearrangement showing no staining or weak cytoplasmic staining. (B) RNA in situ hybridization of CRPC_348 and two 
representative prostatectomies negative for SKIL rearrangement, with probes targeting SKIL mRNA. Nuclei were stained with hematoxylin.
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Expression analysis of the TGF-β and BMP 
pathways (that both converge on SMAD4) revealed 
significantly reduced expression of TGF-β and BMP 
ligands in both untreated and castration resistant prostate 
cancer (Figure 6, Supplementary Figure 3). Other 
genomic alterations in SKIL-positive tumors included 
TP53 mutation in CRPC_348, hemizygous TP53 deletion 
in TCGA-KK-A8IL and TCGA-YL-A8SJ, hemizygous 
PTEN deletion in TCGA-YL-A8SJ, hemizygous NKX3-
1 deletion in TCGA-HC-7211 and TCGA-YL-A8SJ, and 
an MLL3 frameshift deletion mutation in CRPC_348 
(Supplementary Table 4).
In addition to SKIL rearrangements, we found 
various other genomic alterations in our sequencing 
cohort (Figure 7, Supplementary Figure 4, Supplementary 
Table 5). Since the original sequencing did not include 
paired normal tissues, we used targeted sequencing 
on paired blood samples to filter out germline variants. 
The tumor suppressor TP53 was nonsynonymously 
mutated in 2 PCs and 5 CRPCs, with additional loss-
of-heterozygosity in 3 CRPCs. PTEN was disrupted by 
a stopgain mutation in one CRPC sample and deleted 
in eight other tumors. The AR negative tumor PC_6864 
carried a KRAS p.G12R mutation that is known to cause 
constitutive KRAS activation in cancers of the colon, 
pancreas and lungs, but is less common in prostate cancer 
[18]. Sample CRPC_489 harbored two distinct AKT1 
mutations, one of which (p.E17K) has been associated 
with dysregulated tissue growth in the Proteus syndrome 
[19]. We also identified somatic mutations that altered 
the forkhead domain and the N-terminal transactivation 
domain of the AR cofactor FOXA1. Four samples were 
positive for the HOXB13 p.G84E germline variant that has 
been associated with prostate cancer susceptibility [20], 
including one homozygous sample. One AR-negative 
CRPC sample had acquired a DOT1L-HES6 fusion. 
We and others have shown that HES6 overexpression is 
sufficient to induce completely androgen independent 
growth in prostate cancer cells [21,22]. In both PC and 
CRPC, we identified frequent alterations in chromatin 
modifiers including nonsynonymous mutations in CHD4, 
MLL3, HDAC5, KDM5B and MBD6, and a homozygous 
deletion of KDM6A in one sample (Figure 7).
DISCUSSION
SKIL (also known as SnoN) is a 684 amino acid 
Figure 4: In vitro knockdown experiments on SKIL. (A) SKIL expression was silenced in PC3 cells using two siRNAs, resulting in 
(B) reduced growth (n = 4), (C) invasion (n = 4) and (D) colony formation (n = 2). (E) SKIL expression was silenced in LNCaP cells using 
two siRNAs, resulting in (F) reduced growth (n = 4). (G) qRT-PCR time series of SKIL and PSA expression in castrate and non-castrate 
mice carrying LuCaP-77 xenografts (n = 2). Error bars, s.e.m. with first-order error propagation; *P<0.05; **P<0.01; ***P<0.001, unpaired 
two-tailed t-test.
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Figure 6: Genomic and transcriptomic changes in the context of the TGF-β signaling pathway. Genes are shown as boxes 
with two halves: the left half shows the percentage of untreated prostate cancers with two-fold upregulation (red) or downregulation (blue) 
relative to BPH, and the right half shows the same for castration resistant prostate cancers. Arrows indicate interactions between proteins 
or genes, the interaction type is written next to the arrow.
Figure 5: In vitro overexpression experiments on SKIL. (A) Anti-SKIL western blot showing increased SKIL protein in SKIL-
transfected RWPE-1 cells. MCF-7 cells transfected with SKIL or scrambled siRNA are used to validate the band. (B) qRT-PCR quantification 
of SKIL in RWPE-1 cells transfected with SKIL or empty vector. (C) Matrigen invasion assay on RWPE-1 cells transfected with SKIL 
or empty vector (n = 3). Error bars, s.e.m. with first-order error propagation; *P<0.05; **P<0.01; ***P<0.001, unpaired two-tailed t-test.
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nuclear protein that is ubiquitously expressed in human 
tissues [23,24] and shares its domain structure with 
SKI, a protein that was originally discovered through 
its similarity with the transforming component of the 
Sloan-Kettering Virus [25]. Overexpression of either 
SKI or SKIL in chicken embryo fibroblasts is sufficient 
to induce oncogenic transformation [26], and SKIL 
expression is elevated in many human cancers, including 
cancers of the skin, breast, colon and blood [27]. The 
3q26 locus is amplified in several cancer types, and 
SKIL (along with TLOC1) has been highlighted as the 
most potent oncogene in this region [28]. Both SKI and 
SKIL contain an 80 aa SAND-like domain that can bind 
with the MH2 domain of SMAD4 [29]. SMAD4 (co-
Smad) is an irreplaceable part of the heteromeric SMAD 
complexes that act as downstream mediators of TGF-β 
signaling. These heteromeric complexes are formed when 
SMAD4 binds with one or more receptor SMADs such as 
SMAD2 and SMAD3 [29]. The complex then translocates 
to the nucleus and activates transcription of TGF-β 
responsive genes. Binding of SKI/SKIL with the SMAD4 
MH2 domain inhibits this transcriptional activation 
by preventing SMAD complex formation [29] or by 
recruitment of the nuclear co-repressor NCOR1 [16]. In 
addition to its binding with SMAD4, SKIL can also bind 
with the MH2 domains found in receptor SMADs through 
a domain located close to its N-terminal [16]. Neither SKI 
nor SKIL has been shown to directly bind DNA, despite 
both proteins containing a Dachshund homology domain 
that shares features with the forkhead/winged-helix family 
of DNA binding proteins [27].
In addition to the inhibitory role of SKIL on TGF-β 
signaling, a recent study has proposed that SKIL may play 
a role in regulating epithelial-to-mesenchymal transition 
(EMT) by inducing expression of SNAI2 (SLUG), a 
master regulator of EMT [28]. The same study also found 
that SMAD4 knockdown increased the invasiveness 
of human mammary epithelial cells, while SKIL 
overexpression had no effect on cell growth, in agreement 
with our findings [28]. Another recent study has proposed 
that SKIL can interact with and promote the activity of 
estrogen receptor α in the nuclei of breast carcinoma cells. 
The interaction occurs via two highly conserved nuclear 
receptor binding LxxLL-like motifs in SKIL [30]. This 
Figure 7: Characterization of genomic and transcriptomic changes in our prostate cancer sequencing cohort. Expression 
and copy number changes are shown in blue and red. Point mutations and indels affecting protein coding sequences are shown in green. 
White squares indicate missing data.
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finding is intriguing as it suggests a potential interaction 
between SKIL and androgen receptor, as some LxxLL 
motifs can bind with the ligand binding domain of AR 
[31].
The SKIL rearrangements reported in this paper 
occurred in both untreated and castration resistant prostate 
cancers, and involved the 5’ partner genes TMPRSS2, 
SLC45A3, MIPOL1, ACPP, MIPEP and HMGN2P46. The 
androgen regulated genes TMPRSS2 and SLC45A3 are 
the most common 5’ partners involved in ETS fusions in 
prostate cancer [6]. MIPOL1 is another androgen regulated 
gene that is involved in MIPOL1-ETS rearrangements in 
prostate cancers [32]. Expression of ACPP is androgen 
regulated and highly prostate specific among normal 
tissue types [33]. MIPEP is not generally considered 
androgen regulated or highly expressed in the prostate, but 
we observed high expression of both MIPEP and SKIL 
in the MIPEP-SKIL positive sample. HMGN2P46 is a 
pseudogene that is strongly expressed in AR-expressing 
prostate cancers but not expressed in AR-negative cancers 
in our cohort, suggesting an androgen regulated promoter. 
We conclude that six SKIL rearrangements involved 
an androgen regulated promoter, and one involved an 
otherwise highly active promoter.
The discovery of SKIL-activating rearrangements 
in both untreated and castration resistant prostate cancers 
suggests that SKIL rearrangements may represent an 
early event in prostate tumorigenesis. This hypothesis is 
supported by the fact that SKIL rearrangements appear to 
be mutually exclusive with ETS fusions, which represent 
a known early event in prostate cancer progression [34]. 
The complex structure of two rearrangements highlights 
the fact that rearrangements can affect gene expression 
in a clinically significant manner without disrupting 
the transcribed portion of a gene. As an example of 
this complexity, one SKIL-activating rearrangement in 
our study juxtaposed an active promoter to a position 
downstream of SKIL in opposite orientation, and still 
resulted in strongly elevated expression of full length SKIL 
transcript.
Based on the cohorts studied in this manuscript, we 
estimate that SKIL-activating rearrangements are found 
in 1-2% of diagnosed prostate cancers. Due to the high 
incidence of prostate cancer, this fraction translates to 
an estimated 10,000 diagnoses and 3,000 deaths caused 
by SKIL-positive prostate cancers per year worldwide 
[1]. Whether SKIL-positive prostate cancers differ in 
their clinical course from other prostate cancers remains 
to be evaluated in a larger study. Since 6 of 7 SKIL 
rearrangements involved androgen regulated promoters, 
we expect that existing treatment modalities based on 
androgen ablation will be effective at treating SKIL-
rearranged cancers. Nonetheless, SKIL provides an 
intriguing new molecular target for personalized therapy, 
and highlights the role of TGF-β signaling in prostate 
cancer progression.
MATERIALS AND METHODS
Sequencing cohort
Fresh-frozen tissue specimens from 12 benign 
prostate hyperplasias, 28 untreated prostate cancers, and 
13 castration resistant prostate cancers were acquired 
from Tampere University Hospital (Tampere, Finland). 
Untreated prostate cancer samples were obtained by 
radical prostatectomy and locally recurrent CRPCs by 
transurethral resection of the prostate. Samples were 
snap-frozen and stored in liquid nitrogen. Histological 
evaluation and Gleason grading were performed by a 
pathologist based on hematoxylin/eosin-stained slides. 
All samples contained a minimum of 70% cancerous 
or hyperplastic cells. The use of clinical material was 
approved by the ethical committee of the Tampere 
University Hospital and the National Authority for 
Medicolegal Affairs. Written informed consent was 
obtained from the subjects.
Validation cohort
76 additional hormonally untreated PC 
prostatectomy samples were acquired from the Tampere 
University Hospital (Tampere, Finland). Samples were 
snap-frozen and stored in liquid nitrogen. Histological 
evaluation and Gleason grading were performed by a 
pathologist based on hematoxylin/eosin-stained slides. 
Samples were confirmed to contain a minimum of 70% 
cancerous or hyperplastic cells by hematoxylin-eosin 
staining. Mean age at diagnosis was 62.1 years (range: 
47.4-71.8), mean PSA at diagnosis was 11.8 (range: 3.15-
51.5). The use of clinical material was approved by the 
ethical committee of the Tampere University Hospital and 
the National Authority for Medicolegal Affairs. Written 
informed consent was obtained from the subjects.
Cell lines and xenografts
Prostate cancer cell lines PC-3, LNCaP, DU145, 
22Rv1 and immortalized prostate epithelial cell line 
RWPE-1 were obtained from American Type Cell 
Collection (Manassas, VA, USA). LAPC-4 cell line was 
kindly provided by Dr. Charles Sawyers (University of 
California at Los Angeles, Los Angeles, CA, USA), VCaP 
and DuCaP by Dr. Jack Schalken (Radboud University 
Nijmegen Medical Center, Nijmegen, the Netherlands), 
and EP156T by Dr. Varda Rotter (Weizmann Institute 
of Science, Rehovot, Israel). All cell lines were cultured 
under recommended conditions. 22 previously established 
LuCaP-series xenografts were provided by R.L.V. These 
xenografts have been derived from primary and metastatic 
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human prostate cancer and are maintained in vivo [35].
DNA and RNA extraction for sequencing cohort
Fresh-frozen tissue blocks were cut into 10x20-
micrometer sections using a cryotome. RNA and DNA 
were isolated using an AllPrep RNA/DNA minikit 
(Qiagen, Valencia, CA, USA) according to manufacturer’s 
protocol. For some samples, more total RNA was isolated 
using Trizol (Invitrogen, Carlsbad, CA, USA) extraction 
according to manufacturer’s protocol. Three CRPC 
samples had RNA extracted using both Trizol and Qiagen 
AllPrep. The isolated RNA was quantified by based on 
260 nm absorbance and its purity assessed by the 260/280 
nm ratio. Integrity was checked using Bioanalyzer 
(Agilent Technologies, Santa Clara, CA, USA). Reverse 
transcription of RNA to cDNA from clinical samples 
was carried out using SuperScript(TM)III (Invitrogen, 
Carlsbad, CA, USA) reverse transcriptase and AMV 
(Finnzymes, Espoo, Finland) for cell line samples with 
random hexamer primers according to manufacturer’s 
instructions. 
Whole genome library construction and 
sequencing
Genomic DNA was sonicated into 500 bp fragments 
using a Covaris E210. Overhangs were converted into 
blunt ends using T4 DNA polymerase and Klenow 
enzyme. An adenine was added to the 3’ end of the blunt 
phosphorylated DNA fragments, and adapters were ligated 
on both ends. Ligated products were purified by agarose 
gel electrophoresis followed by QIA quick gel extraction, 
to remove residual free and self-ligated adaptors and to 
select properly sized templates for cluster generation. DNA 
fragments with adapters on both ends were amplified using 
two primers that annealed to the adapters. PCR products 
were checked and purified by agarose gel electrophoresis. 
The fragment size and molar concentration of each 
library was determined using Agilent 2100 Bioanalyzer 
and ABI Real-Time PCR System (StepOnePlusTM), 
respectively. As mean fragment size increased to 622 bp 
after adapter ligation, fragments between 600 bp and 684 
bp were selected. An Illumina Cluster Station was used 
to hybridize samples onto a flow cell and amplify them 
for sequencing on Illumina HiSeq™ 2000. Raw image 
files were processed by Illumina pipeline for base-calling 
with default parameters resulting in 90 bp paired end 
reads. Reads with too many N bases (>10%) or low base 
quality (>50% bases with base quality <5) were discarded. 
Library construction and sequencing was performed at the 
Beijing Genomics Institute (BGI), Hong Kong.
Whole transcriptome library construction and 
sequencing
Beads with Oligo(dT) were used to isolate poly(A) 
mRNA after collection of total RNA. Fragmentation buffer 
was added to shear mRNA into short fragments and to 
synthesize the first-strand cDNA with random hexamer 
primers. The second-strand cDNA was synthesized 
using buffer, dNTPs, RNaseH, and DNA polymerase I, 
respectively. Short fragments were purified with QiaQuick 
PCR extraction kit and resolved with EB buffer for end 
reparation and poly(A) addition. After that, the short 
fragments were ligated to sequencing adapters and suitable 
fragments were selected for the PCR amplification as 
templates and separated with agarose gel electrophoresis 
before sequencing. Raw image files were processed by 
Illumina pipeline for base calling with default parameters 
resulting in 90 bp paired end reads. Reads with too many 
N bases (>10%) or low base quality (>50% bases with 
base quality <5) were discarded. Library construction 
and sequencing was performed at the Beijing Genomics 
Institute (BGI), Hong Kong.
Fusion gene analysis
To achieve robust results, fusion gene discovery was 
performed using two different strategies. First, we applied 
ChimeraScan [36] to the raw FASTQ format sequencing 
data. ChimeraScan used an installed instance of Bowtie 
0.12.8 [37] for read alignment. Anchor length was 
specified as 25 bp. One nucleotide mismatch was allowed 
in the initial alignments and in the alignment of discordant 
reads. Fusion gene candidates with less than 20 spanning 
reads were filtered out in order to focus the analysis on 
strongly expressed fusion genes.
Second, we used an in-house fusion detection 
algorithm called Breakfast to validate the ChimeraScan 
results and to search for more complex rearrangement. 
The Breakfast algorithm operates on aligned SAM files, 
and therefore we first aligned our whole transcriptome 
sequencing reads against the GRCh37 human reference 
genome using Tophat version 2.0.4 [38]. Breakfast 
searched the alignments for discordant read pairs and 
unaligned individual mates. For discordant read pairs, we 
required the mates to be at least one megabase apart. The 
alignment quality of both mates in a discordant pair was 
required to be above 15 phred. Next, individual unaligned 
mates were split into two 25 bp anchors that were extracted 
from both ends of each 90 bp mate. The 25 bp anchors 
were then re-aligned against the GRCh37 human reference 
genome using Bowtie 0.12.8 [37], and the resulting 
alignments were searched for evidence of discordantly 
aligned anchor pairs. Breakfast then constructed clusters 
of evidence for chromosomal rearrangements using both 
discordant read pairs and anchor pairs. To produce the 
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final list of rearrangement candidates, we filtered out any 
rearrangements that were not supported by at least 1 paired 
read and 5 anchor pairs, or by at least 20 anchor pairs.
Sanger sequencing of TMPRSS2-SKIL fusion
The TMPRSS2-SKIL junction was amplified 
from cDNA using Phusion™ High-Fidelity DNA 
polymerase (Finnzymes, Espoo, Finland) and primers 
5’-AGTAGGCGCGAGCTAAGCAG-3’ (forward) and 
5’-CAATGCAATGGTCTGGTTTG-3’ (reverse). PCR 
cycling was performed as follows: 98 °C for 30-60 seconds 
followed by 35 cycles of 98°C for 7 seconds, 56-58°C for 
30 seconds, 72°C for 30 seconds, and a final extension for 
5 minutes using GC-buffer, with a final volume of 25 µl. 
The size of each amplicon was verified with 1% Agarose 
gel. Target amplicons were purified using QIAquick 
PCR purification columns (Qiagen Inc, Valencia, CA, 
USA) and then sequenced using the BigDye® Terminator 
v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster 
City, CA, USA) and the ABI PRISM® 3100 sequencer 
(Applied Biosystems, Foster City, CA, USA) according to 
manufacturer’s instructions.
SKIL expression analysis using qRT-PCR
cDNA synthesis was performed from 1 µg 
of total RNA using SuperScript(TM) III Reverse 
Transcriptase (Invitrogen, Carlsbad, CA, USA) and 
random hexamer primers (Thermo Scientific, Waltham, 
MA, USA) according to manufacturers’ instructions. 
Synthesized cDNA was diluted 1:20 to nuclease free 
water and expression was measured using Bio-Rad 
CFX96 Real Time System. The final reaction mixture 
(22 µl) contained 2 µl cDNA, 0.125 µl forward 
(5’-AGAGGCTGAATATGCAGGACA-3’) and reverse 
(5’-CCAAAGCAAGCAACAAACAA-3’) primers and 
11 µl 2X SYBR Green qPCR Master Mix and RNAse 
free ddH2O. NTC (No Template Control) was used 
during the reaction to detect DNA contamination. PCR 
cycling was performed as follows: 95 °C for 20 seconds 
followed by 55 cycles of 95°C for 10 seconds, 58°C for 10 
seconds, 72°C for 8 seconds, followed by melting curve 
analysis. Finally the size of the amplicon was checked 
using 1.5% agarose gel electrophoresis. SKIL expression 
was normalized relative to the TATA-box binding protein 
(TBP) reference gene.
Fluorescence in situ hybridization
Frozen 5-7 µm sections of prostate cancer tissue 
were fixed by Carnoy fixation (Carnoy fixative: 1/3 acetic 
acid glacial/methanol, 50%, 75%, 2 x 100%, 15 min 
each), denatured in 70% formamide/2xSSC at 72-75°C 
for 3-5 min and air dried. BAC clones were obtained 
from Life Technologies. Fusion probes (RP11-814F13, 
upstream of TMPRSS2, and RP11-922G14, overlapping 
and downstream of SKIL) as well as break-apart probes 
(CTD-2562E3, upstream of SKIL, and RP11-469J4 
downstream of SKIL) were used. The probes were labeled 
by nick translation with ChromaTide Alexa Fluor 594-5-
dUPT or digoxigenin-11-dUTP (Roche Diagnostics, Basel, 
Switzerland). After hybridization for two days at 37°C the 
slides were washed and stained with anti digoxigenin-
FITC. The slides were embedded in Vectashield antifade 
solution (Vector Laboratories, Burlingame, CA, USA) 
containing 0.1M 4,6-diamidino-2-phenylindole (DAPI) 
as a counterstain and the signals were scored with an 
Olympus BX5 epifluorescence microscope equipped with 
a charge-coupled device camera. Stacks of seven images 
were captured with each filter set with Image-Pro Plus 6.1 
software (Media Cybernetics, Inc., Rockville, MD, USA) 
and combined to produce an RGB image with an extended 
depth of focus.
SKIL western blot
Cells were lysed in RIPA buffer (Thermo Scientific) 
including protease and phosphatase inhibitors (Halt 
Protease&Phosphatase Inhibitor cocktail, Thermo 
Scientific). Protein concentrations were measured with 
DC Protein Assay (BioRad), 4x SDS sample buffer was 
added and 40 µg of protein lysate was loaded into each 
well. SDS-PAGE and protein transfer to nitrocellulose 
membranes were carried out according to standard 
protocols. Blocking was achieved with 5% milk, TBS, 
0.1% Tween. Anti-SnoN (dilution 1:1000, ab128079, 
Abcam), anti-β-tubulin I (dilution 1:20000, T7816, Sigma-
Aldrich), and polyclonal HRP-conjugated rabbit anti-
mouse (dilution 1:2000, P0161, Dako) antibodies were 
used for protein detection.
SKIL immunohistochemistry 
SKIL-protein levels were validated from paraffin-
embedded prostate cancer tissues using monoclonal 
mouse antibody (1:700, [2F6] (ab128079), Abcam plc, 
Cambridge, UK) with Power Vision+ Poly-HRP IHC kit 
(Immunologic, AD Duiven, the Netherlands) according to 
the manufacturer’s instructions. Prior to staining, sections 
were deparaffinized and autoclaved in 10 mM of sodium 
citrate buffer, pH 6.0. Slides were scanned with an Aperio 
ScanScope XT scanner (Aperio Technologies, Inc.).
RNA in situ hybridization
FFPE tissue sections were treated according to 
manufacturer’s instructions using RNAscope® 2.0 HD 
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Detection Kit - BROWN (Advanced Cell Diagnostics, 
Inc., Hayward, CA, USA). Briefly, slides were first 
deparaffinized in xylene and dehydrated in 100% ethanol. 
Sections were then pretreated and boiled in 50mM Tris 
1mM EDTA-solution containing 0.05% Tween using 
Lab Visionᵀᴹ PT Module (Thermo Fisher Scientific Inc., 
Waltham, MA, USA). Next, a target probe for SKIL 
mRNA (P/N 427981, Advanced Cell Diagnostics, Inc.) 
and signal amplifiers were hybridized using HybEZ 
Oven (Advanced Cell Diagnostics, Inc.). A probe for 
Peptidylprolyl isomerase B (PPIB, P/N 427981, Advanced 
Cell Diagnostics, Inc.) was used as a positive control and 
a probe for dihydrodipicolinate reductase (DapB, P/N 
310093, Advanced Cell Diagnostics, Inc.) was used as 
a negative control in every assay. Signal detection was 
performed using DAB substrate as a chromogen. Slides 
were counterstained with 50% Mayer’s hematoxylin (Oy 
FF-Chemicals Ab) and blue color was intensified with 
TBS-Tween. Finally, slides were dehydrated in an ethanol 
series and mounted. Slides were scanned with an Aperio 
ScanScope XT scanner (Aperio Technologies, Inc.).
Small interfering RNA knockdown of SKIL
The knockdown of SKIL expression was done 
using small interfering RNA (AM16708, ID 107695) 
from Ambion (Ambion, Austin, TX, USA). The siRNA 
sequences (5’-to-3’) were:
1: GGCAAGUAAGUCCAUAUCATT (sense) and 
UGAUAUGGACUUGCCTC (antisense)
2: GGCUCACAGUAGUGGUAATT (sense) and 
UUACCACUACUGUGAGCCTT (antisense)
Silencer® Negative Control #1 siRNA (AM4611, 
Ambion, Austin, TX, USA) was used as a non-targeting 
control. Cells were seeded into 24-well plates (30000 cells/
well) in four replicates and were transfected the following 
day with 50 nM SKIL siRNA and scrambled siRNA. 
INTERFERin TM (PolyPlus Transfection, Strasbourg, 
France) and Opti-MEM were used for cell transfection. 
Growth curve analysis
Cells were plated on 12-well plate (30 000 cells on 
each well) as quadruplicates and each well was scanned 
daily using the Surveyor Software (Objective Imaging 
Ltd.) with a camera (Imaging Inc., Canada) attached to the 
Olympus IX71 (Olympus, Tokyo, Japan) microscope and 
the area of the attached cells in each well was computed 
using ImageJ Software (Wayne Rasband, National 
Institutes of Health, Bethesda, MD) and divided by the 
mean area for day 1.
Cell invasion assay
The effect of SKIL knockdown in PC-3 cells and 
overexpression in RWPE-1 cells on cell invasion were 
evaluated in BioCoat Matrigel Invasion chambers (BD 
Biosciences, Bedford, MA, USA) coated with a basement 
membrane matrix. Matrigel was rehydrated in growth 
medium for 2 h at 37 °C and 5% CO2. Transfected cells 
(10,000 PC-3 or 20,000 RWPE-1) were harvested and 
resuspended in 1% FBS (PC-3 cells) or Keratinocyte 
Serum Free Medium (RWPE-1 cells), and placed in the 
upper chamber of the transwell. The lower chamber 
contained a 750 μl medium with 10% FBS and 5 μg/ml 
fibronectin (PC-3 cells) or 0.05 mg/ml BPE and 5 ng/ml 
EGF (RWPE-1 cells). The cells were then incubated for 
22 h at 37 °C in 5% CO2. Cells in the top well of the 
upper chamber were wiped off the top membrane with 
cotton swabs. The membranes were then fixed with 3.7% 
formaldehyde (PC-3 cells) or 100% methanol (RWPE-1 
cells) and stained with 1% toluidine for 15 min at room 
temperature for visualization of cells. Cells that had 
invaded to the lower surface were photographed and 
counted under a microscope.
Colony formation assay
PC-3 cells transfected with SKIL or scrambled 
siRNA were grown on 6-well plates in duplicate (5000 
cells/well). Briefly, base agar containing 1% agar dissolved 
in Ham’s F-12 mixed with 20% FBS, 2% L-glutamine 
and 2% penicillin-streptomycin and 1 ml mixture was 
transferred into the well. Then the top layer containing 
0.7% agar including 10% FBS, 1% L-glutamine and 
1% penicillin-streptomycin was prepared. Top agar was 
mixed with suspended cell line and transferred over 
base agar. Base and top agar were covered with normal 
growth medium and incubated at 37°C and 5% CO2 
for 15 days. After incubation, colonies were fixed with 
3.7% formaldehyde and stained with 0.1% toluidine 
blue. Excess dye was removed by washing with 10 mM 
phosphate buffer (pH 7.4).
Transfection of SKIL into RWPE-1 cells
To study the effects of SKIL overexpression, pCI-
Neo HA-hSnoN plasmid (a gift from Robert Weinberg, 
Addgene plasmid #10908 [17]) and universal empty, 
pCI-Neo backbone pUNIV-plasmid (a gift from Cynthia 
Czajkowski, Addgene plasmid #24705 [39]) were 
stably transfected into RWPE-1 cells (ATCC, cultured 
under the recommended conditions) with jetPEI® 
polymer-based DNA transfection reagent (POLYPLUS-
TRANSFECTION Inc., New York, NY, USA) according 
to the manufacturer’s instructions. Transfected clones were 
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selected with 400 µg/ml geneticin (G418, Invitrogen Inc., 
Carlsbad, CA, USA) over several weeks, after which SKIL 
mRNA levels were determined using qRT-PCR and the 
clone showing the highest overexpression of SKIL mRNA 
was selected for further analysis. Control RWPE-1 cells 
were transfected with empty pCI-Neo backbone vector. All 
transfected cells were subsequently cultured after selection 
in a medium containing geneticin (200 µg/ml).
Calculation of gene expression
RNA-seq reads were aligned against RefSeq 38 
human transcript sequences using Bowtie version 2.0.0-
beta6 [40]. Expression values were normalized across 
all samples using median-of-ratios normalization. Read 
counts for a given gene were divided by the total length 
of the gene’s exons (in kilobases) to correct for gene size 
bias. For some genes, we observed a strong and systematic 
expression bias associated with the two different RNA 
isolation methods we used (Trizol and Qiagen AllPrep 
kits). To correct for this bias, we took the BPH samples 
from which we had extracted RNA using both Trizol and 
Qiagen, and calculated an expression ratio for all genes by 
dividing the median expression in the Trizol group by the 
median expression in the Qiagen group. We then used an 
unpaired t-test to look for genes differentially expressed 
between Trizol and Qiagen treated samples. Genes with a 
p-value less than 0.0001 were considered sensitive to the 
RNA isolation method, and their expression levels were 
corrected by dividing the expression of Trizol samples 
with the Trizol/Qiagen expression ratio.
Copy number analysis
DNA-seq reads were aligned against GRCh37 using 
Bowtie version 2.0.0-beta6 [40]. Aligned read counts were 
calculated within overlapping 500 bp windows along the 
whole genome. Coverage logratios were calculated within 
each window by comparing against read count averages 
from four BPH controls. To normalize logratios within 
copy neutral regions to zero, we applied a median filter 
of length 50 to the logratios in each sample, rendered 
logratio histograms for each chromosome, and took the 
median of the histogram modes. This value was then 
subtracted from all logratios for that sample. Frequently 
aberrant chromosomes 8, 22, X, and Y were not included 
in calculating the median of modes. Coverage logratios 
for individual genes were calculated by taking the median 
logratio over all intragenic windows. If a gene’s length was 
shorter than 20 kb, the median window was extended on 
both sides so as to reach a length of 20 kb. Logratios were 
converted into copy number changes using the formula 
(ploidy * 2^logratio - ploidy), where ploidy was based on 
the chromosome in which the gene or genomic region was 
located. Copy number changes were further multiplied by 
(1 / 0.7) to correct for the estimated 70% tumor sample 
purity in our samples. A gene was considered to be 
amplified or deleted if the corrected copy number change 
had an absolute value above 0.5.
Computational identification of putative somatic 
mutations
We first used RNA-seq data to search for mutations 
in transcribed loci, and then validated putative variants 
using DNA-seq data. RNA-seq reads were aligned against 
GRCh37 using Tophat version 2.0.2 [38] and Bowtie 
version 2.0.0-beta6 [40]. Duplicate reads were discarded 
using samtools rmdup, and variants were called using an 
in-house pipeline. Low quality alignments (MAPQ < 10) 
were ignored for PC and CRPC samples, but were used 
for variant calling in BPH control samples. A genomic site 
was called heterozygous alternate in PC and CRPC if at 
least four reads and at least 15% of all reads at that site 
showed an alternate allele. In BPH samples, a genomic site 
was considered heterozygous if at least 2 reads and at least 
5% of all reads showed an alternate allele. Any variants 
found in BPH samples were considered to be germline 
variants and filtered out. We also filtered out any variants 
found in the 1000 Genomes project [41], the NHLBI 
Exome Sequencing Project (ESP6500, unpublished, 
http://evs.gs.washington.edu/EVS/), or the SISU project 
(unpublished, http://www.sisuproject.fi/). The VCF file 
produced by samtools was annotated using the ANNOVAR 
software [42] and custom scripts. For every variant, we 
predicted functional impact and identified features in the 
genomic neighborhood. We also determined whether the 
variant was found in the COSMIC database [43] for cancer 
associated mutations.
Illumina MiSeq targeted validation of somatic 
mutations
Sequencing libraries were prepared using the the 
Illumina TruSeq Custom Amplicon Kit following the 
TruSeq Custom Amplicon Library Preparation Guide. 
For most samples, 250 ng of DNA was used. Custom 
probes flanking 677 target variants were designed using 
the DesignStudio software (Illumina). Probes were 
designed so as to yield amplicons with a mean size of 250 
bp. Targets were extended from one probe and ligated to 
the second probe. Next, during two rounds of synthesis, 
sample-specific indexes were incorporated, producing 
dsDNA molecules containing two unique indexes and 
flanking amplification sequences. Libraries were then 
generated using the following PCR program: 95°C for 
180 seconds, 24 cycles of 95°C for 30 seconds, 66°C 
for 30 seconds, 72°C for 60 seconds, and 72°C for 5 
minutes, then cooling to 10°C. Resulting libraries were 
cleaned up (45 µl of AMPure XP beads for each library) 
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and normalized according to manufacturer’s guidelines. 
Library quality was verified with an Agilent Bioanalyzer 
(Agilent Santa Clara, CA, USA) using a DNA 1000 chip. 
Finally, all libraries were pooled and diluted 1:100 before 
loading into a MiSeq instrument (Illumina, San Diego, 
CA, USA) for sequencing. The reagent kit used was the 
MiSeq® Reagent Kit v2 (500 cycle). 
Data access
The European Genome-phenome archive database 
accession number for the high throughput sequencing data 
reported in this paper is EGAS00001000526.
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